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ABSTRACT  – Calcium blockers are used in cardiovascular diseases, usually in long term
treatments and sometimes in pregnant women. Isradipine is an important antihypertensive drug,
considered to be safe in pregnancy. In this study, the effects of isradipine were evaluated regarding
to the uterine implantation, fetal reabsorption, plasmatic levels of calcium, phosphate and total
protein of mother and offspring.  Thirty-two female and 12 male quality-controlled Wistar rats
were used. The drug was administered in drinking water for 56 days: 35 days before mating and
21 days along the pregnancy.  In one group, caesarean surgery was performed on the 20th//day
and in the other, isradipine treatment continued for the naturally born rats, which were observed
along 30 days. During the caesarean, blood samples of mothers and newborns were taken and
plasmatic / levels of calcium, phosphate and total proteins determined. To observe the drug
influence on the bones, femur mineralization of mothers was evaluated. Results showed that
isradipine stimulated uterine implantation; however, it increased the fetal reabsorption. No
teratogenic effect was observed but newborns displayed a lower body weight. Plasmatic levels
of calcium, phosphate and total proteins were not influenced by the drug. Dental eruption was
not disturbed in the offspring born from the treated mothers.
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RESUMO – Os bloqueadores de cálcio são utilizados em doenças cardiovasculares, usualmente
em tratamentos de longa duração e ocasionalmente em mulheres grávidas. A isradipina é uma
importante droga antihipertensiva, considerada segura na gravidez e sem efeitos teratogênicos.
Neste estudo foram estudados, em ratos Wistar, os efeitos da isradipina sobre a implantação
uterina, reabsorção fetal e sobre os níveis plasmáticos de cálcio, fosfato e proteínas totais.
Foram utilizados 32 fêmeas e 12 machos  com qualidade controlada. A droga foi administrada
na água de beber durante 56 dias, sendo 35 antes do acasalamento e 21 durante a prenhêz. Em
um grupo, foi realizada operação cesareana ao 20º / dia de gestação e em outro, os ratos
nasceram de parto natural e foram observados durante 30 dias, com manutenção da
administração de isradipina. Por ocasião da cesareana foram obtidas amostras de sangue de
mães e filhotes, para determinação de cálcio, fosfato e proteínas totais plasmáticas. Para
observar a influência da droga no / tratamento prolongado sobre os ossos, a mineralização do
fêmur das mães foi avaliada. Os resultados mostraram que a isradipina estimulou a implantação
uterina porém aumentou a reabsorção fetal. Nenhum efeito teratogênico foi observado, entretanto
ocorreu diminuição significativa do peso dos filhotes. Os níveis plasmãticos de cálcio, fosfato e
proteínas totais não foram alterados pela droga. O período da erupção dental não foi alterado
nos  filhotes nascidos de mães tratadas.
Palavras chaves: isradipine, bloqueadores, antagonistas Ca, gestação.
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Introduction
Calcium channel blockers are important
therapeutic agents, used as vasodilator and
antiarrhythmic drugs, usually in long term
treatments. They act by inhibiting  the slow
voltage-dependent of L-type (NOWICKY et
al., 1985) in vascular smooth muscle, in a
lower concentration than those required to
interfere with the release of intracellular Ca2+
or to block receptor-operated channels, then,
preventing ionized calcium from entering the
cells and thus influencing calcium-dependent
processes (FLECKESTEIN et al., 1967,
1969; KERINS et al., 2003). All Ca2+ channel
blockers relax the arterial smooth muscle but
have little effect on most venous beds. They
act on cardiac cells by disturbing excitation-
contraction coupling by a different mechanism,
since in the heart, in the portion of the two
inward currents, it is carried by Na+ through
the fast channel in addition to that carried by
Ca2+ through the slow channel. Although all
blocking channel drugs share similar
pharmacological properties, some are
somewhat more specific as antihypertensive
and others as antiarrhythmic. Verapamil was
the first channel blocker clinically used and it
is important nowadays as antiarrhythmic.
Isradipine is indicated in hypertension, a
condition in which it is considered by some
authors as a first choice (HAMILTON, 1987;
SAUTER and RUDIN, 1989, 1990; SOLAND,
1990; LUSCHER and WAEBER, 1991;
SCHACHTER, 1991). An extensive revision
on the pharmacology and clinical research of
calcium antagonists was published by
VANHOUTTE et al., (1988). These drugs,
indicated in chronic diseases, are often used
in pregnant women, in which they are
considered to be safe. Isradipine
pharmacokinetics allows a continuous
therapeutic activity for 24 hours in a single
administration, with excellent tolerability and
low side-effects (HANSON and DAHLOF,
1987; SOLAND, 1990). No teratogenic effect
has been described for the use of this drugs
in rats a significant reduction in body weight
and in the number of offspring born from
verapamil treated mothers (VILELA-
GOULART et al., 1999a). An interest arises
whether calcium antagonists influence the
calcium balance in bone or not. There is a
great medical interest referring to the
possibility of such drugs to be a risk factor for
the development or aggravation of
osteoporosis. However, a few studies refer
to its influence on bone tissue. Receptors of
the L type channels in osteoblasts were
proposed by GRYGORCZYK et al., (1989)
and calcium receptors and/or calcium
channels were suggested to occur in the
osteoclasts  (DATTA et al.,1990; RITCHIE et
al., 1994). Other authors referred to the
subject (HERMANN-ERLEE et al., 1977;
LERNER and GUSTAFSON, 1982;
SIMEKOVA et al., 1987; CHAGNAC et al.,
1989; ZAIDI et al., 1989, 1990; DURRIEZ et
al., 1990; RITCHIE et al., 1994). It was
reported by SAMNEGARD and SJÖDEN
(1992) that verapamil increases bone volume
and osteopenia in female rats but has the
opposite  effect in male rats. It was described
by VILELA-GOULART et al., (1999 b) that
verapamil increases mothers´ femoral bone
mineralization in female rats and induced a
significant delay in their newborns´ dental
eruption. In the present paper, it was intended
to study the effects on pregnancy and
offspring of a calcium blocker isradipine, of
the dihydropiridine group, in order to compare
results with those obtained with verapamil, of
the   phenylalkylamine group.
Material and Methods
To the experiments, 44 Wistar rats (Rattus
norvegicus, var. albinus) in controlled good
health conditions were used. Thirty-two were
virgin females, aged 90-100 days at the onset
of the experiments and 12 were reproductive
male rats. The female were divided in two
groups: treated with isradipine and not treated,
running in parallel (control). Isradipine was
administered during 35 days before mating
and 21 days during pregnancy.   The drug was
added to the drinking water in doses of 1.0
mg/rat/day.  All the animals were weekly
weighted and behavior observed. In a group
of rats the administration of the drug continued
for 30 days after the  natural delivery.   After 7
weeks of treatment and the estrous phase
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determined, female and male rats were put
together overnight for mating; diagnosis of
pregnancy was determined by presence of
spermatozoa in the vaginal secretion. At the
20th  day of pregnancy, the uterus of mothers
were exposed by caesarean surgery under
anesthesia (ketamine, 100 mg/Kg and
xylazine, 3.0 mg/Kg) and observed both the
number of alive newborn and dead fetuses,
and the embryonic reabsorption and uterine
embryonic implantation (= number of embryos
+ number of embryonic reabsorption). The
ovary was removed and the number of
corresponding ovules released during
fertilization was counted. The newborn rats
were cleaned, weighed and somatic external
characteristics examined under 3 X
magnification. Ears and eyes implantation,
palate, labial cleft, anterior and posterior limbs
and tail were examined.  Blood samples were
taken in heparin from mothers and newborn.
Mother’s femoral bone was removed and
freed of adherent soft tissues; length, fresh
and dry weight measured. Biochemical
determination of calcium, inorganic phosphate
and total proteins were carried out in plasma
obtained from mothers and new-born, using a
Beckman-Du 600 Spectrophotometer.
Plasmatic calcium was determined by
compleximetric method of O-cresolphtalein-
complexon  using Merck Reagents. To
plasmatic inorganic phosphate  determination,
FISKE and SUBAROW (1925) method was
used. Total proteins were determined by Biuret
method, using a “Bioclin” kit reagents. Dental
eruption in young was observed by thickening
of gingival epithelium in “U” shape.
Significance of the difference between groups
was assessed by Student “t” test.
Results
1 - Fetal uterine implantation and fetal
reabsorption. The mean number of  fetal
uterine implantation in control mothers  was
of  11.51(±1.19). In treated mothers this mean
significantly raised to 13.3(±1.3). This uterine
implantation was correspondent to the number
of ovarian luteinizing bodies. No uterine
reabsorption was observed in the control
mothers but in the treated ones, fetal
reabsorption of  27 % was observed.
2 - Alive offspring and somatic
characteristics. In control rats, alive newborn
corresponded to 100% of uterine implantation.
However, in isradipine treated group, the alive
offsprings  was significantly reduced in 27 %.
The body  weight of offspring born from the
treated mothers was at birth, 12 % lesser than
in the control and 30 days after the birth it
continued to be significantly lower as
compared to control.  No macroscopic
malformations in control and treated newborn
were observed and no sign of intoxication or
behavioral disturbance occurred in the
isradipine treated mothers as well as in their
newborns up to 30 days after birth (TABLES
1 and 2).
TABLE 1 – UTERINE IMPLANTATION, FETAL REABSORPTION AND ALIVE OFFSPRING (MEAN
VALUES) OF CONTROL AND ISRADIPINE (1.0MG/DAY/RAT) TREATED RATS  FOR 56
DAYS.
Control (n=8) Isradipine (n=8)
Uterine implantation 11.5 (± 1.19) 13.0 (± 1.30)
Fetal reabsorption Zero   3.5  (± 3.02)
Alive offspring 11.5 (± 1.19)   9.5  (± 3.96)
TABLE 2 – BODY WEIGHT (G) OF ALIVE NEWBORN AT BIRTH (CESAREAN BORN-ZERO DAYS OF
LIFE) AND AT THE 30TH DAY OF LIFE (NATURAL DELIVERANCE). CONTROL AND
ISRADIPINE (1.0 MG/DAY/RAT) TREATED MOTHERS.
Control(n=8) Isradipine (n=8)
At birth (zero days)   6.73 (± 0.44)   5.93 (± 0.74)
30th days of life 75.67 (± 6.33)  60.71 (± 3.06)
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3 - Femoral bone length, fresh and dry
weights. The length, fresh and dry weight of
femoral bone was not significantly influenced
by isradipine treatment (TABLE 3).
4 - Dental eruption. Dental eruption period
did not differ between control and isradipine
treated animals, occurring at the 9th day of birth.
5 - Plasmatic calcium, phosphate and
proteins. Plasmatic calcium, inorganic
phosphate and total protein were not changed
in mothers treated with isradipine. Regarding
to the newborn rats, the values of plasmatic
inorganic phosphate was 102 % higher at birth
as compared to their respective mothers and
returned to normal values at the 30th day of
age (TABLE 4).
TABLE 3 – LENGTH (MM), FRESH AND DRY FEMORAL WEIGHTS (MG) OF MOTHER RATS: CONTROL
AND TREATED WITH ISRADIPINE (1.0 MG/DAY/RAT) FOR 56 DAYS (A) AND 86 DAYS (B).
      Control (n=8) Isradipine (n= 8)
       ( A )
Length   26.00 (± 4.07)   26.75 (± 3.65)
Fresh weight 680.62 (± 55.19) 691.87 (± 55.54)
Dry weight 370.00 (± 37.45) 376.25 (± 40.68)
       ( B )
Length  30.37 (± 5.84)   28.37 (± 6.81)
Fresh weight 718.12 (±107.96) 724.37 (± 87.80)
Dry weight  347.50 (± 42.67) 350.00 (± 46.59)
TABLE 4 – PLASMATIC VALUES (MEAN) OF CALCIUM, INORGANIC PHOSPHATE (MG/100ML) AND
TOTAL PROTEINS (G/100 ML) OF MOTHER RATS (A) AND OFFSPRING (B) OF CONTROL
AND ISRADIPINE (1.0MG/DAY/RAT) TREATED FOR 56 (CESAREAN) AND 84 DAYS
(NATURAL BIRTH).
56 days (n=8) ( cesarean ) 84 days (n=8) ( natural birth )
Control Isradipine Control Isradipine
     ( A )
Calcium 6.04 (± 1.28) 5.93 (± 1.16) 5.04  (± 0.88) 4.91 (± 0.70)
Phosphate 3.81 (± 1.16) 3.75 (± 2.59) 3.13  (± 0.41) 3.69 (± 2.47)
Total protein 6.54 (± 0.88) 6.17 (± 2.01) 5.82  (± 0.75) 5.60 (± 0.70)
    ( B )
Calcium 5.08  (±1.08) 6.60 (± 2.50) 4.83 (± 0.44) 4.52 (± 0.90)
Phosphate 7.68  (± 2.36) 7.72 (± 3.19) 3.07 (± 0.49) 4.00 (± 0.51)
Total protein 5.69  (± 1.00) 4.96 (± 2.18) 5.51 (± 0.73) 5.03 (± 0.63)
Discussion
There is a great medical, scientific and social
interest  in the teratogenic effect of drugs given
to mothers during  pregnancy. Regarding to
calcium channel blockers, usually given in  long
term treatments,  an adding interest refers to
the possibility of such drugs to be a risk factor
for the development or aggravation of
osteoporosis, a crippling bone disease that
poses  as a major public health problem.
Although  studies about a role of calcium blocking
channels in bone cells and tissue have been
carried out (HERMANN-ERLEE et al., 1977;
LERNER and GUSTAFSON, 1982;
SIMEKOVA  et al.,1987; CHAGNAC et al.,
1989; ZAIDI et al., 1989, 1990; DURRIEZ et
al., 1990; DATTA et al., 1990; SAMNEGARD
and SJÖDEN, 1992; RITCHIE et al., 1994; ),
the possible influence of these agents on the
mineralization of the teeth  has been described
by VILELA-GOULART et al., (1999 b), using
verapamil. Being aware of  the effects of these
substances on some bone cells calcium cytosol,
we decided to study the influence of isradipine,
an important widely used calcium blocking agent
on pregnancy, on bone mineralization, on dental
eruption and the possible repercussion on
offspring born from treated mothers. We
previously observed (VILELA-GOULART et al.,
1999 b) that in pregnant rats, the femur became
more densely mineralized  in verapamil treated
rats and dental germ eruption was significantly
delayed. Our result could be compared with
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those of FOX and DELLA-SANTINA (1989) and
SAMNEGARD and SJÖDEN (1992) who
reported in rats given verapamil an increase in
tibial bone mineralization (as ash  per volume)
in male rats. However, the latter authors,
studying the influence of sex, found an opposite
results to female, that is, bone mineralization
was significantly reduced by verapamil. They
attributed such differences  to a possible action
of the drug in stimulating androgen secretion,
absent in the female. In our experiments with
verapamil it was observed a different result: the
drug increased bone mineralization in the
females, a result we attributed to the rats being
pregnant and in this condition, there is a
physiological higher absorption (BROMMAGE
et al., 1990) which could induce a higher
mineralization. However, calcium plasmatic
values were not changed by isradipine and the
drug failed in increasing bone growth and
mineralization, a result that coud be attributed
to the doses used or to isradipine itself.
Isradipine, different of what was observed with
verapamil, did not retard dental eruption in
newborn, suggesting no influence on the organ
organization. The doses of the drug used in our
experiments can be considered adequate,
because during the long term treatment, i.e. 56
or 86 days, the rats seemed to thrive and
increase their body weight and no disturbed
behavior was observed.
Calcium-phosphate balance is essential to
rat normal bone mineralization (McCOY,
1949). The dietary calcium-phosphate was
adequate as shown by normal growth of
control and treated rats. It is well known that
the ratio of calcium to phosphorous in the diet
exerts a marked effect upon growth and
calcium and phosphorous content in the blood
serum. No sign of rickets were observed. The
daily dietary calcium phosphate was within the
range proposed by McCOY (1949) to normal
development of the rat. Isradipine did not
influence plasmatic calcium and phosphate
either in mothers or in offsprings, results quite
different of those obtained with verapamil
(VILELA-GOULART et al., 1999a). However,
in control and treated groups, phosphate was
significantly higher, (about 100 %) in offspring
at birth, values returning to normal, being
comparable to their mothers at the 30th days of
age. The increase in ovulation and embryonic
uterine implantation in verapamil treated rats
was a very consistent  finding. However, such
implantation did not correspond to the fetuses
at term, since a high degree of uterine
reabsorption occurred. Results are suggestive
in indicating that isradipine stimulated ovarian
follicles, liberating immature ovules, which were
fertilized but did not succeed in giving rise to
functional ovum and fetus. One can speculate
whether isradipine enhanced ovulation by itself,
influencing calcium-dependent mechanisms or
acted, like verapamil, by indirectly stimulating
luteinizing hormone or follicle stimulating
hormone, which respond to ovulation and
corpora lutea formation. Or the drug could act
by inhibiting atresia of ovarian follicles not
destined to produce functional ovum. One must
consider that the present results, although
consistent and significant, are not sufficient to
a further discussion, but are suggestive to
inspire future research. As observed with
verapamil (VILELA-GOULART et al., (1999a),
isradipine induced significant uterine
reabsorption. One can speculate that the drug
acted during blastogenesis, which occur in the
rat from the 1st to the 6th day, a susceptible period
when toxic action of drugs leads to embryo death
and fetal reabsorption. The drug did not certainly
acted during organogenesis (after the 6th day),
because in doing so, it could lead to fetal
malformations, a response not observed with
isradipine.
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